What is Retatrutide (LY3437943)? Retatrutide is a cutting-edge, investigational peptide developed by Eli Lilly. It functions as a first-in-class “GGG triagonist,” meaning it simultaneously activates three critical metabolic receptors: GLP-1, GIP, and glucagon. This unique triple-action approach creates a powerful synergistic effect on metabolic health and weight management.
Key Research Highlights:
-
Exceptional Weight Reduction: Phase 2 clinical trials demonstrated unprecedented results, with up to 24.2% body weight loss over a 48-week period.
-
Comprehensive Mechanism: Promotes weight loss by reducing appetite, delaying gastric emptying, increasing energy expenditure, and driving targeted fat breakdown.
-
Cardiometabolic Support: Research indicates strong improvements in insulin sensitivity, lipid profiles, and blood pressure regulation.
-
Metabolic Research Focus: Widely recognized as one of the most promising current candidates for the treatment of severe obesity and related metabolic disorders.
